Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Siskind

Showing results (231-240 of 292) with videos related to

Pageof 30
Sort By:
Focus (American Psychiatric Publishing)|September 6, 2021
The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled TrialsDavy Vancampfort, Joseph Firth, Christoph U Correll, et al.
Epidemiology and Psychiatric Sciences|November 17, 2022
Colorectal cancer treatment in people with severe mental illness: a systematic review and meta-analysisMelinda M Protani, Meshary Khaled N Alotiby, Rebecca Seth, et al.
Bjpsych Open|April 27, 2026
SMART: preliminary efficacy, feasibility and acceptability of a theory-informed digital intervention for metabolic health in people with schizophrenia and related disordersUrska Arnautovska, Gabrielle Ritchie, Nicole Korman, et al.
CNS Drugs|September 11, 2025
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized TrialMatin Mortazavi, Zahra Aminifarsani, Inge Winter-van Rossum, et al.
CNS Spectrums|December 20, 2024
Clozapine rechallenge following myocarditis: a systematic review of rechallenge casesLaura McMahon, Maddison Giudice, Elias Wagner, et al.
Schizophrenia Bulletin|March 21, 2023
Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working GroupElias Wagner, Dan Siskind, Peter Falkai, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 15, 2025
Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis - ADDENDUMElias Wagner, Nicole Korman, Marco Solmi, et al.
The Australian and New Zealand Journal of Psychiatry|January 16, 2026
<i>Australian and New Zealand Journal of Psychiatry</i> Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophreniaShuichi Suetani, Frances Dark, Susanna Every-Palmer, et al.
The Lancet. Psychiatry|June 12, 2025
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in AustraliaDan Siskind, Andrea Baker, Urska Arnautovska, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 2, 2025
Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditisElias Wagner, Nicole Korman, Marco Solmi, et al.
Pageof 30

Showing results (231-240 of 292) with videos related to

Sort By:
Pageof 30
Focus (American Psychiatric Publishing)|September 6, 2021
The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled TrialsDavy Vancampfort, Joseph Firth, Christoph U Correll, et al.
Epidemiology and Psychiatric Sciences|November 17, 2022
Colorectal cancer treatment in people with severe mental illness: a systematic review and meta-analysisMelinda M Protani, Meshary Khaled N Alotiby, Rebecca Seth, et al.
Bjpsych Open|April 27, 2026
SMART: preliminary efficacy, feasibility and acceptability of a theory-informed digital intervention for metabolic health in people with schizophrenia and related disordersUrska Arnautovska, Gabrielle Ritchie, Nicole Korman, et al.
CNS Drugs|September 11, 2025
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized TrialMatin Mortazavi, Zahra Aminifarsani, Inge Winter-van Rossum, et al.
CNS Spectrums|December 20, 2024
Clozapine rechallenge following myocarditis: a systematic review of rechallenge casesLaura McMahon, Maddison Giudice, Elias Wagner, et al.
Schizophrenia Bulletin|March 21, 2023
Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working GroupElias Wagner, Dan Siskind, Peter Falkai, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 15, 2025
Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis - ADDENDUMElias Wagner, Nicole Korman, Marco Solmi, et al.
The Australian and New Zealand Journal of Psychiatry|January 16, 2026
<i>Australian and New Zealand Journal of Psychiatry</i> Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophreniaShuichi Suetani, Frances Dark, Susanna Every-Palmer, et al.
The Lancet. Psychiatry|June 12, 2025
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in AustraliaDan Siskind, Andrea Baker, Urska Arnautovska, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 2, 2025
Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditisElias Wagner, Nicole Korman, Marco Solmi, et al.
Pageof 30